Cargando…
280. The Impact of a Revised Neutropenic Fever Guideline on Vancomycin-Resistant Enterococcus Rates in Pediatric Oncology Patients
BACKGROUND: Data on the impact of empiric febrile neutropenia (FN) guidelines on resistant bacteria in pediatric oncology patients are limited. We implemented a risk-stratified guideline for empiric FN antibiotics, limiting vancomycin use to high-risk patients for 48 hours if cultures were negative....
Autores principales: | Karandikar, Manjiree, Milliren, Carly, Zaboulian, Robin, Sharma, Tanvi, Place, Andrew, Sandora, Thomas J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254063/ http://dx.doi.org/10.1093/ofid/ofy210.291 |
Ejemplares similares
-
Evaluating Initial Empiric Therapy for Neutropenic Fever in Vancomycin-Resistant Enterococcus-Colonized Patients
por: Snyder, Matthew, et al.
Publicado: (2021) -
Empiric Vancomycin Use in Febrile Neutropenic Oncology Patients
por: Libuit, Jessica, et al.
Publicado: (2014) -
Evaluation of a Risk Stratification Guideline for the Treatment of Neutropenic Fever in Oncology Patients
por: Wollenziehn, Amber, et al.
Publicado: (2017) -
Vancomycin Dosing in Neutropenic Patients
por: Haeseker, Michiel B., et al.
Publicado: (2014) -
Neutropenic Fever
por: Baluch, Aliyah, et al.
Publicado: (2019)